Medical technology company XVIVO Perfusion AB (STO:XVIVO) announced on Wednesday the receipt of European patent approval for the company's ready-to-use product Perfadex Plus for cold preservation of lungs.

Patent applications for the new formulation have been submitted in all important markets and the European patent authority has now approved the patent in Europe.

Perfadex Plus was launched in the principal markets, the US and Europe, in 2018 and the work on regulatory approval for Perfadex Plus is ongoing, with the aim that the product is approved in all markets in 2019.

According to the company, Perfadex has been the market standard for lung preservation for more than 15 years and has been marketed by XVIVO Perfusion since 1999. Perfadex Plus is now taking over this market-leading role in those markets where the product is approved. It is used for cold preservation of lungs, that is rinsing away donor blood and keeping the donated lungs in good condition at a cold temperature during transportation and preservation before transplantation.

XVIVO Perfusion added that the advantage of Perfadex Plus is that it is a complete fluid that is used without the clinic adding buffer and calcium ions before use. This facilitates administration and reduces the risk of improper use.

XVIVO Perfusion develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.